Status:
COMPLETED
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
Lead Sponsor:
Light Sciences Oncology
Conditions:
Carcinoma, Hepatocellular
Liver Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether the Litx™ treatment is safe and effective in treating inoperable hepatocellular carcinoma (HCC). Litx™ is an integrated treatment system comprising a...
Detailed Description
Subjects that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on thei...
Eligibility Criteria
Inclusion
- A diagnosis of primary Hepatocellular Carcinoma (HCC), established by any one of the following criteria in a clinical setting suggestive of HCC: (i) Two different imaging techniques that suggests HCC; (ii) Combination of one imaging technique that suggests HCC and serum alpha-fetoprotein (AFP) level \>400 ng/mL; (iii) Histological evidence of HCC;
- Subjects with at least 1 but no more than 3 lesions in the liver may be considered for enrollment in the study;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
- Life expectancy of at least 16 weeks;
- Prior treatment failure with locally ablative techniques is allowed. Subjects who were not candidates for surgery, systemic chemotherapy, chemoembolization (TACE), intratumoral ethanol injection (PEI), radiofrequency ablation (RFA), cryoablation or other locally ablative technology may be eligible, but at least 4 weeks must have elapsed since the completion of any prior therapy and the subject must have recovered from acute side effects;
- Understanding and ability to sign written informed consent;
- 18 years of age or more;
- Adequate hematologic, liver and renal functions as evidenced by the following: \*WBC \> 2,400/mm; \*Platelet Count \> 75,000/µl; \*Hemoglobin \> 9.4 gm/dL; \*PT and PTT \< 1.5 Control; \*AST, ALT \< 5 x ULN; \*Bilirubin \< 1.5 X ULN; \*Alk Phos \< 3X ULN; \*Creatinine \< 2.5 mg/dL (SI: 221 mmol/L)
Exclusion
- Subjects who are candidates for surgery with curative intent;
- Subjects with lesions larger than 8 cm in diameter and more than 40% of parenchymal disease involvement;
- Known sensitivity to porphyrin type drugs;
- Known history of porphyria;
- Known presence of extrahepatic metastases;
- Anticipated need for systemic chemotherapy during the first 8 weeks of the study;
- Child-Pugh C cirrhosis;
- Diffuse HCC;
- Concurrent participation in another clinical trial involving experimental treatment;
- Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which in the Principal Investigator's opinion could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial's data.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00122876
Start Date
April 1 2005
End Date
October 1 2006
Last Update
December 7 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong
2
National Cancer Centre Singapore
Singapore, Singapore
3
Singapore General Hospital
Singapore, Singapore
4
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan